CD81, a cell cycle regulator, is a novel target for histone deacetylase inhibition in glioma cells

Neurobiology of Disease

Volumn 26, Issue 3, 2007, Pages 671-680

  Gensert, JoAnn M ^a,b   Baranova, Oxana V ^a   Weinstein, David E ^c   Ratan, Rajiv R ^a,b  

^a Burke Cornell Medical Research Institute   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c GliaMed Inc   (United States)

Author keywords

Acetylation; Astrocyte; Glioma; HDAC; Proliferation

Indexed keywords

BUTYRIC ACID; CD81 ANTIGEN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; RNA; TRICHOSTATIN A;

ANIMAL CELL; ARTICLE; ASTROCYTE; CELL CYCLE; CELL DEATH; CELL DIFFERENTIATION; CONTROLLED STUDY; CYTOSTASIS; ENZYME INACTIVATION; GLIOMA CELL; GROWTH DISORDER; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RNA INTERFERENCE;

ANIMALS; ANTIGENS, CD; BRAIN NEOPLASMS; BUTYRATES; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DOWN-REGULATION; ENZYME INHIBITORS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; GENES, CDC; GLIOMA; HISTONE DEACETYLASES; HYDROXAMIC ACIDS; RATS; RATS, INBRED F344; RATS, WISTAR; RNA INTERFERENCE;

EID: 34248582299     PISSN: 09699961     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nbd.2007.03.008     Document Type: Article

References (67)

1. Baylin S.B., and Herman J.G. DNA hypermethylation in tumorigenesis: epigenetics joins genetics. Trends Genet. 16 (2000) 168-174
2. Benda P., Someda K., Messer J., and Sweet W.H. Morphological and immunochemical studies of rat glial tumors and clonal strains propagated in culture. J. Neurosurg. 34 (1971) 310-323
3. Boismenu R., Rhein M., Fischer W.H., and Havran W.L. A role for CD81 in early T cell development. Science 271 (1996) 198-200
4. Boucheix C., and Rubinstein E. Tetraspanins. Cell. Mol. Life Sci. 58 (2001) 1189-1205
5. Cacoub P., Bourliere M., Hausfater P., Charlotte F., Khiri H., Toci S., Piette J.C., Poynard T., and Halfon P. Lower expression of CD81 B-cell receptor in lymphoproliferative diseases associated with hepatitis C virus infection. J. Viral Hepatitis 10 (2003) 10-15
6. Costello J.F. DNA methylation in brain development and gliomagenesis. Front. Biosci. 8 (2003) s175-s184
7. Drucker L., Tohami T., Tartakover-Matalon S., Zismanov V., Shapiro H., Radnay J., and Lishner M. Promoter hypermethylation of tetraspanin members contributes to their silencing in myeloma cell lines. Carcinogenesis 27 (2006) 197-204
8. Esteller M. CpG island hypermethylation and tumor suppressor genes: a booming present, a brighter future. Oncogene 21 (2002) 5427-5440
9. Esteller M., Catasus L., Matias-Guiu X., Mutter G.L., Prat J., Baylin S.B., and Herman J.G. hMLH1 promoter hypermethylation is an early event in human endometrial tumorigenesis. Am. J. Pathol. 155 (1999) 1767-1772
10. Esteller M., Garcia-Foncillas J., Andion E., Goodman S.N., Hidalgo O.F., Vanaclocha V., Baylin S.B., and Herman J.G. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N. Engl. J. Med. 343 (2000) 1350-1354
11. Esteller M., Silva J.M., Dominguez G., Bonilla F., Matias-Guiu X., Lerma E., Bussaglia E., Prat J., Harkes I.C., Repasky E.A., Gabrielson E., Schutte M., Baylin S.B., and Herman J.G. Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J. Natl. Cancer Inst. 92 (2000) 564-569
12. Esteller M., Fraga M.F., Paz M.F., Campo E., Colomer D., Novo F.J., Calasanz M.J., Galm O., Guo M., Benitez J., and Herman J.G. Cancer epigenetics and methylation. Science 297 (2002) 1807-1808
13. Eyupoglu I.Y., Hahnen E., Buslei R., Siebzehnrubl F.A., Savaskan N.E., Luders M., Trankle C., Wick W., Weller M., Fahlbusch R., and Blumcke I. Suberoylanilide hydroxamic acid (SAHA) has potent anti-glioma properties in vitro, ex vivo and in vivo. J. Neurochem. 93 (2005) 992-999
14. Finnin M.S., Donigian J.R., Cohen A., Richon V.M., Rifkind R.A., Marks P.A., Breslow R., and Pavletich N.P. Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature 401 (1999) 188-193
15. Fleisher A.S., Esteller M., Wang S., Tamura G., Suzuki H., Yin J., Zou T.T., Abraham J.M., Kong D., Smolinski K.N., Shi Y.Q., Rhyu M.G., Powell S.M., James S.P., Wilson K.T., Herman J.G., and Meltzer S.J. Hypermethylation of the hMLH1 gene promoter in human gastric cancers with microsatellite instability. Cancer Res. 59 (1999) 1090-1095
16. Fotakis G., and Timbrell J.A. In vitro cytotoxicity assays: comparison of LDH, neutral red, MTT and protein assay in hepatoma cell lines following exposure to cadmium chloride. Toxicol. Lett. 160 (2006) 171-177
17. Geisert Jr. E.E., Yang L., and Irwin M.H. Astrocyte growth, reactivity, and the target of the antiproliferative antibody, TAPA. J. Neurosci. 16 (1996) 5478-5487
18. Geisert Jr. E.E., Abel H.J., Fan L., and Geisert G.R. Retinal pigment epithelium of the rat express CD81, the target of the anti-proliferative antibody (TAPA). Invest Ophthalmol. Visual Sci. 43 (2002) 274-280
19. Geisert Jr. E.E., Williams R.W., Geisert G.R., Fan L., Asbury A.M., Maecker H.T., Deng J., and Levy S. Increased brain size and glial cell number in CD81-null mice. J. Comp. Neurol. 453 (2002) 22-32
20. Grant P.A. A tale of histone modifications. Genome Biol. 2 (2001) 3.1-3.6
21. Hemler M.E. Tetraspanin proteins mediate cellular penetration, invasion, and fusion events and define a novel type of membrane microdomain. Annu. Rev. Cell Dev. Biol. 19 (2003) 397-422
22. Herman J.G., Merlo A., Mao L., Lapidus R.G., Issa J.P., Davidson N.E., Sidransky D., and Baylin S.B. Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res. 55 (1995) 4525-4530
23. Herman J.G., Jen J., Merlo A., and Baylin S.B. Hypermethylation-associated inactivation indicates a tumor suppressor role for p15INK4B. Cancer Res. 56 (1996) 722-727
24. Herman J.G., Civin C.I., Issa J.P., Collector M.I., Sharkis S.J., and Baylin S.B. Distinct patterns of inactivation of p15INK4B and p16INK4A characterize the major types of hematological malignancies. Cancer Res. 57 (1997) 837-841
25. Herold C., Ganslmayer M., Ocker M., Hermann M., Geerts A., Hahn E.G., and Schuppan D. The histone-deacetylase inhibitor trichostatin A blocks proliferation and triggers apoptotic programs in hepatoma cells. J. Hepatol. 36 (2002) 233-240
26. Hoshikawa Y., Kwon H.J., Yoshida M., Horinouchi S., and Beppu T. Trichostatin A induces morphological changes and gelsolin expression by inhibiting histone deacetylase in human carcinoma cell lines. Exp. Cell Res. 214 (1994) 189-197
27. Inoue G., Horiike N., and Onji M. The CD81 expression in liver in hepatocellular carcinoma. Int. J. Mol. Med. 7 (2001) 67-71
28. Ito N., Sawa H., Nagane M., Noguchi A., Hara M., and Saito I. Inhibitory effects of sodium butyrate on proliferation and invasiveness of human glioma cells. Neurosurgery 49 (2001) 430-437
29. Jones L.J., Gray M., Yue S.T., Haugland R.P., and Singer V.L. Sensitive determination of cell number using the CyQUANT cell proliferation assay. J. Immunol. Methods 254 (2001) 85-98
30. Kelic S., Levy S., Suarez C., and Weinstein D.E. CD81 regulates neuron-induced astrocyte cell-cycle exit. Mol. Cell. Neurosci. 17 (2001) 551-560
31. Kim Y.B., Yoshida M., and Horinouchi S. Selective induction of cyclin-dependent kinase inhibitors and their roles in cell cycle arrest caused by trichostatin A, an inhibitor of histone deacetylase. Ann. N. Y. Acad. Sci. 886 (1999) 200-203
32. Korzeniewski C., and Callewaert D.M. An enzyme-release assay for natural cytotoxicity. J. Immunol. Methods 64 (1983) 313-320
33. Kristeleit R., Stimson L., Workman P., and Aherne W. Histone modification enzymes: novel targets for cancer drugs. Expert Opin. Emerg. Drugs 9 (2004) 135-154
34. Lashford L.S. Possibilities of gene therapies for cancer. Ann. Med. 29 (1997) 1-4
35. Levitz S.M., and Diamond R.D. A rapid colorimetric assay of fungal viability with the tetrazolium salt MTT. J. Infect. Dis. 152 5 (1985) 938-945
36. Lobner D. Comparison of the LDH and MTT assays for quantifying cell death: validity for neuronal apoptosis?. J. Neurosci. Methods 96 (2000) 147-152
37. 2+-chelating motif-tethered short-chain fatty acids as a novel class of histone deacetylase inhibitors. J. Med. Chem. 47 (2004) 467-474
38. Marks P.A., Richon V.M., and Rifkind R.A. Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. J. Natl. Cancer Inst. 92 (2000) 1210-1216
39. Marks P., Rifkind R.A., Richon V.M., Breslow R., Miller T., and Kelly W.K. Histone deacetylases and cancer: causes and therapies. Nat. Rev., Cancer 1 (2001) 194-202
40. Marks P.A., Richon V.M., Breslow R., and Rifkind R.A. Histone deacetylase inhibitors as new cancer drugs. Curr. Opin. Oncol. 13 (2001) 477-483
41. Marks P.A., Rifkind R.A., Richon V.M., and Breslow R. Inhibitors of histone deacetylase are potentially effective anticancer agents. Clin. Cancer Res. 7 (2001) 759-760
42. Miyazaki T., Muller U., and Campbell K.S. Normal development but differentially altered proliferative responses of lymphocytes in mice lacking CD81. EMBO J. 16 (1997) 4217-4225
43. Morgan D.M. Tetrazolium (MTT) assay for cellular viability and activity. Methods Mol. Biol. 79 (1998) 179-183
44. Munster P.N., Troso-Sandoval T., Rosen N., Rifkind R., Marks P.A., and Richon V.M. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells. Cancer Res. 61 (2001) 8492-8497
45. Narayan G., Arias-Pulido H., Koul S., Vargas H., Zhang F.F., Villella J., Schneider A., Terry M.B., Mansukhani M., and Murty V.V. Frequent promoter methylation of CDH1, DAPK, RARB, and HIC1 genes in carcinoma of cervix uteri: its relationship to clinical outcome. Mol. Cancer 2 (2003) 24-35
46. Oren R., Takahashi S., Doss C., Levy R., and Levy S. TAPA-1, the target of an antiproliferative antibody, defines a new family of transmembrane proteins. Mol. Cell. Biol. 10 (1990) 4007-4015
47. Peixoto P., and Lansiaux A. Histone-deacetylases inhibitors: from TSA to SAHA. Bull. Cancer 93 (2006) 27-36
48. Qiu L., Kelso M.J., Hansen C., West M.L., Fairlie D.P., and Parsons P.G. Anti-tumour activity in vitro and in vivo of selective differentiating agents containing hydroxamate. Br. J. Cancer 80 (1999) 1252-1258
49. Sakajiri S., Kumagai T., Kawamata N., Saitoh T., Said J.W., and Koeffler H.P. Histone deacetylase inhibitors profoundly decrease proliferation of human lymphoid cancer cell lines. Exp. Hematol. 33 (2005) 53-61
50. Sawa H., Murakami H., Ohshima Y., Murakami M., Yamazaki I., Tamura Y., Mima T., Satone A., Ide W., Hashimoto I., and Kamada H. Histone deacetylase inhibitors such as sodium butyrate and trichostatin A inhibit vascular endothelial growth factor (VEGF) secretion from human glioblastoma cells. Brain Tumor Pathol. 19 (2002) 77-81
51. Sawa H., Murakami H., Kumagai M., Nakasato M., Yamauchi S., Matsuyama N., Tamura Y., Satone A., Ide W., Hashimoto I., and Kamada H. Histone deacetylase inhibitor, FK228, induces apoptosis and suppresses cell proliferation of human glioblastoma cells in vitro and in vivo. Acta Neuropathol. (Berl.) 107 (2004) 523-531
52. Schmidek H.H., Nielsen S.L., Schiller A.L., and Messer J. Morphological studies of rat brain tumors induced by N-nitrosomethylurea. J. Neurosurg. 34 (1971) 335-340
53. Sibenaller Z.A., Etame A.B., Ali M.M., Barua M., Braun T.A., Casavant T.L., and Ryken T.C. Genetic characterization of commonly used glioma cell lines in the rat animal model system. Neurosurg. Focus 19 (2005) E1-E9
54. -/- mice. J. Cell. Biochem. 92 (2004) 1160-1170
55. Sriwilaijaroen N., Kelly J.X., Riscoe M., and Wilairat P. Cyquant cell proliferation assay as a fluorescence-based method for in vitro screening of antimalarial activity. Southeast Asian J. Trop. Med. Public Health 35 (2004) 840-844
56. Stipp C.S., Kolesnikova T.V., and Hemler M.E. Functional domains in tetraspanin proteins. Trends Biochem. Sci. 28 (2003) 106-112
57. Su G.H., Sohn T.A., Ryu B., and Kern S.E. A novel histone deacetylase inhibitor identified by high-throughput transcriptional screening of a compound library. Cancer Res. 60 (2000) 3137-3142
58. Sullivan C.D., and Geisert Jr. E.E. Expression of rat target of the antiproliferative antibody (TAPA) in the developing brain. J. Comp. Neurol. 396 (1998) 366-380
59. Suzuki T., Yokozaki H., Kuniyasu H., Hayashi K., Naka K., Ono S., Ishikawa T., Tahara E., and Yasui W. Effect of trichostatin A on cell growth and expression of cell cycle- and apoptosis-related molecules in human gastric and oral carcinoma cell lines. Int. J. Cancer 88 (2000) 992-997
60. Takahashi S., Doss C., Levy S., and Levy R. TAPA-1, the target of an antiproliferative antibody, is associated on the cell surface with the Leu-13 antigen. J. Immunol. 145 (1990) 2207-2213
61. Toledo M.S., Suzuki E., Handa K., and Hakomori S. Cell growth regulation through GM3-enriched microdomain (glycosynapse) in human lung embryonal fibroblast WI38 and its oncogenic transformant VA13. J. Biol. Chem. 279 (2004) 34655-34664
62. 4 and increased DNase I sensitivity of the associated DNA sequences. Proc. Natl. Acad. Sci. U. S. A. 75 (1978) 2239-2243
63. Wang X.M., Terasaki P.I., Rankin Jr. G.W., Chia D., Zhong H.P., and Hardy S. A new microcellular cytotoxicity test based on calcein AM release. Hum. Immunol. 37 (1993) 264-270
64. Weng W.K., and Levy S. Hepatitis C virus (HCV) and lymphomagenesis. Leuk. Lymphoma 44 (2003) 1113-1120
65. Yamashita Y., Shimada M., Harimoto N., Rikimaru T., Shirabe K., Tanaka S., and Sugimachi K. Histone deacetylase inhibitor trichostatin A induces cell-cycle arrest/apoptosis and hepatocyte differentiation in human hepatoma cells. Int. J. Cancer 103 (2003) 572-576
66. Yokomine T., Shirohzu H., Purbowasito W., Toyoda A., Iwama H., Ikeo K., Hori T., Mizuno S., Tsudzuki M., Matsuda Y., Hattori M., Sakaki Y., and Sasaki H. Structural and functional analysis of a 0.5-Mb chicken region orthologous to the imprinted mammalian Ascl2/Mash2-Igf2-H19 region. Genome Res. 15 (2005) 154-165
67. Yoshida M., Kijima M., Akita M., and Beppu T. Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. J. Biol. Chem. 265 (1990) 17174-17179